BioCentury
ARTICLE | Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

September 2, 2020 1:18 AM UTC

House oversight committee to subpoena AbbVie for pricing documents

The U.S. House Committee on Oversight and Reform disclosed plans to issue a subpoena to AbbVie Inc. (NYSE:ABBV) for documents regarding pricing strategies for autoimmune drug Humira adalimumab and cancer therapy Imbruvica ibrutinib. The pharma dipped $3.56 to $92.24 on Tuesday...